Guizhou Bailing Group Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Guizhou Bailing Group Pharmaceutical Co Ltd cash flow-to-debt ratio. Guizhou Bailing Group Pharmaceutical Co Ltd (002424) has a Cash Flow-to-Debt Ratio of 0.10x as of September 2025, meaning its operating cash flow of CN¥294.76 Million could theoretically repay 0% of its total liabilities (CN¥3.00 Billion) in one year. Check 002424 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Guizhou Bailing Group Pharmaceutical Co Ltd (2007–2025)
Cash flow-to-debt ratio of Guizhou Bailing Group Pharmaceutical Co Ltd from 2007 to 2025. Historical debt coverage capacity for Guizhou Bailing Group Pharmaceutical Co Ltd across 19 annual periods. Check Guizhou Bailing Group Pharmaceutical Co (002424) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Guizhou Bailing Group Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2007–2025)
Guizhou Bailing Group Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2007 to 2025. Year-by-year debt coverage analysis for Guizhou Bailing Group Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Guizhou Bailing Group Pharmaceutical Co (002424) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.25x | CN¥748.72 Million | CN¥3.02 Billion | ▲ +10707.0% |
| 2024 | 0.00x | CN¥9.02 Million | CN¥3.94 Billion | ▼ -93.0% |
| 2023 | 0.03x | CN¥125.77 Million | CN¥3.82 Billion | ▼ -81.0% |
| 2022 | 0.17x | CN¥502.15 Million | CN¥2.90 Billion | ▲ +34.9% |
| 2021 | 0.13x | CN¥324.92 Million | CN¥2.53 Billion | ▲ +72.5% |
| 2020 | 0.07x | CN¥231.78 Million | CN¥3.11 Billion | ▼ -53.6% |
| 2019 | 0.16x | CN¥467.41 Million | CN¥2.91 Billion | ▲ +309.1% |
| 2018 | -0.08x | CN¥-157.45 Million | CN¥2.05 Billion | ▼ -230.2% |
| 2017 | 0.06x | CN¥79.88 Million | CN¥1.36 Billion | ▼ -85.2% |
| 2016 | 0.40x | CN¥466.62 Million | CN¥1.17 Billion | ▲ +11.9% |
| 2015 | 0.36x | CN¥413.23 Million | CN¥1.16 Billion | ▲ +9.5% |
| 2014 | 0.33x | CN¥395.83 Million | CN¥1.22 Billion | ▲ +210.1% |
| 2013 | 0.10x | CN¥141.76 Million | CN¥1.35 Billion | ▲ +543.4% |
| 2012 | 0.02x | CN¥19.52 Million | CN¥1.20 Billion | ▼ -91.3% |
| 2011 | 0.19x | CN¥201.90 Million | CN¥1.08 Billion | ▲ +139.8% |
| 2010 | -0.47x | CN¥-447.68 Million | CN¥952.49 Million | ▼ -267.1% |
| 2009 | 0.28x | CN¥125.31 Million | CN¥445.48 Million | ▲ +323.2% |
| 2008 | -0.13x | CN¥-40.42 Million | CN¥320.72 Million | ▲ +49.8% |
| 2007 | -0.25x | CN¥-79.37 Million | CN¥315.87 Million | — |